High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer

Mollavelioglu, Baran; Cetin Aktas, Esin; Cabioglu, Neslihan; Abbasov, Aykhan; Onder, Semen; Emiroglu, Selman; Tükenmez, Mustafa; Muslumanoglu, Mahmut; Igci, Abdullah; Deniz, Gunnur; Ozmen, Vahit

doi:10.1186/s12957-022-02810-z

Table 4 Demographic, clinical, and pathological features and ICR expressions on tumor-infiltrating CD16⁺CD56^dim NK cell subset

From: High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer

	CD16⁺CD56^dim NK cells		PD-1⁺ NK cells		CTLA-4⁺ NK cells		TIGIT⁺ NK cells		LAG-3⁺ NK cells		TIM-3⁺ NK cells
	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p
Age
≤ 50 (n:18)	4 (0.5–15)	0.38	6.6 (0–32)	0.93	14.5 (0–67)	0.73	3.5 (0–14)	0.33	2.9 (0–24)	0.02	13 (1.3–75)	0.92
> 50 (n:14)	5.5 (1–37)	0.38	5.8 (0.8–30)	0.93	10 (0.5–70)	0.73	4 (0–67)	0.33	18.5 (0–58)	0.02	13.5 (0–55)	0.92
Menopausal status
Pre (n:17)	4.6 (0.5–15)	0.98	7 (0–32)	0.97	15 (0–67)	0.74	3,6 (0–35)	0.49	3 (0–34)	0.22	15 (1.3–75)	0.86
Post (n:15)	5 (1–37)	0.98	6 (0.8–30)	0.97	11 (0.5–70)	0.74	4 (0–67)	0.49	5.3 (0–58)	0.22	13 (0–55)	0.86
HER-2
Negative (n:21)	3.6 (0.5–12)	0.07	7.2 (0–32)	0.35	14 (0–70)	0.29	4 (0–64)	0.78	3 (0–58)	0.27	15 (0–75)	0.59
Positive (n:11)	6 (1.3–37)	0.07	5.5 (0.4–24)	0.35	6.9 (0.5–67)	0.29	2.8 (1–67)	0.78	16 (0.8–57)	0.27	8 (1.3–60)	0.59
Ki-67
≤ 20 (n:5)	1.3 (1–4)	0.03	12 (4–30)	0.35	36 (3.6–70)	0.07	2.8 (0–4)	0.14	18 (0–30)	0.91	40 (0–60)	0.51
> 20 (n:27)	5 (0.5–37)	0.03	6 (0–32)	0.35	11 (0–40)	0.07	4 (0–67)	0.14	3.4 (0–58)	0.91	13 (0.6–75)	0.51
Histologic grade
Grade 2 (n:10)	3.7 (1–11)	0.17	11.5 (4.8–32)	0.03	28.5 (3.6–70)	0.02	4 (0–35)	0.80	15 (0–30)	0.52	18 (0–60)	0.32
Grade 3 (n:22)	5 (0.5–37)	0.17	5.9 (0–32)	0.03	10 (0–40)	0.02	3.7 (0–60)	0.80	3 (0–58)	0.52	9.3 (0.6–75)	0.32
High TIL density (>%10)
Negative (n:20)	3.5 (0.5–11)	0.002	8.1 (0–32)	0.22	14 (0–70)	0.15	4 (0–35)	0.69	11 (0–34)	0.54	15.5 (0–75)	0.37
Positive (n:12)	10 (1.5–37)	0.002	5.9 (0.4–24)	0.22	7 (0.5–40)	0.15	2.7 (0.4–67)	0.69	3 (1–58)	0.54	8.7 (1.3–28)	0.37
Luminal
Negative (n:6)	5 (2–37)	0.28	6.5 (4–14)	0.82	34.5 (0.5–67)	0.06	4.5 (0.4–35)	0.86	2.8 (1.1–34)	0.62	17.7 (3–60)	0.38
Positive (n:26)	4.3 (0.5–15)	0.28	6 (0–32)	0.82	10.1 (0–70)	0.06	4 (0–67)	0.86	4.8 (0–58)	0.62	13.5 (0–75)	0.38
T stage
T1 (n:9)	1.5 (0.5–15)	0.28	6 (0.4–24)	0.62	9 (1–40)	055	4 (1–35)	0.40	16 (0.8–34)	0.40	8 (1.6–40)	0.95
T2 (n:23)	5 (1–37)	0.28	6 (0–32)	0.62	13 (0–70)	055	4 (0–67)	0.40	3 (0–58)	0.40	14 (0–75)	0.95
N stage
N0 (n:23)	5 (0.5–37)	0.8	6 (0–24)	0.11	9.2 (0–70)	0.52	3.4 (0–67)	0.45	3.4 (0–57)	0.39	11 (0–75)	0.73
N1 (n:9)	4.6 (1–11)	0.8	10 (1–32)	0.11	14 (1–37)	0.52	4 (2–64)	0.45	5.3 (1.8–58)	0.39	15 (1.3–55)	0.73
Lympho-vascular invasion
Negative (n:16)	5.7 (1–37)	0.3	6 (0.4–32)	0.67	9.1 (0.5–70)	0.49	3.5 (0–64)	0.52	3.2 (0–58)	0.66	12 (0–40)	0.46
Positive (n:16)	4 (0.5–12)	0.3	7.1 (0–32)	0.67	14.5 (0–67)	0.49	4.5 (0–67)	0.52	10.7 (0–57)	0.66	14.8 (1.6–75)	0.46
Extensive intraductal component
Negative (n:21)	5 (0.5–12)	0.13	6 (0.8–32)	0.84	12 (1–70)	0.93	4 (0–64)	0.75	5.3 (0–58)	1	11 (0–40)	0.08
Positive (n:11)	3.6 (1–37)	0.13	7 (0–30)	0.84	13 (0–67)	0.93	3.4 (0–67)	0.75	3 (0–57)	1	15 (3–75)	0.08

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us